While exempting 17 cancer medicines from basic customs duty was welcome, there is little evidence to suggest that companies passed on the benefit to the customers in earlier instances
While exempting 17 cancer medicines from basic customs duty was welcome, there is little evidence to suggest that companies passed on the benefit to the customers in earlier instances